Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metoprolol in HFrEF and COPD
NCT06825728Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of metoprolol in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Composite endpoints (all-cause death and rehospitalization) at 24 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
metoprolol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06825728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825728.